MCID: CRB138
MIFTS: 37

Core Binding Factor Acute Myeloid Leukemia malady

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

About this section

Core Binding Factor Acute Myeloid Leukemia, Aliases & Descriptions:

Name: Core Binding Factor Acute Myeloid Leukemia 21
Cbf Acute Myeloid Leukemia 21
 
Core-Binding Factor Aml 21
Cbf-Aml 21


Summaries for Core Binding Factor Acute Myeloid Leukemia

About this section


Genetics Home Reference:21 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets.

MalaCards based summary: Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to myeloid leukemia and systemic mastocytosis. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), and among its related pathways are Hematopoietic cell lineage and Development FGFR signaling pathway. The compounds tandutinib and pkc 412 have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone, and related mouse phenotypes are craniofacial and liver/biliary system.

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

About this section

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
idRelated DiseaseScoreTop Affiliating Genes
1myeloid leukemia30.9CBFB, RUNX1, FLT3, JAK2, KIT, HRAS
2systemic mastocytosis30.8KIT, JAK2
3leukemia30.4KIT, HRAS, CBFB, JAK2, FLT3, RUNX2
4hematopoietic stem cell transplantation10.5
5mastocytosis10.5
6myeloid sarcoma10.3FLT3, KIT
7mast cell neoplasm10.3FLT3, KIT
8precursor b-cell acute lymphoblastic leukemia10.2FLT3, KIT
9myelofibrosis10.2JAK2
10gastrointestinal stromal tumor10.2KIT, FLT3
11neurofibromatosis10.2KIT, HRAS
12acute myelomonocytic leukemia10.2RUNX1, CBFB
13acute lymphoblastic leukemia, childhood10.1RUNX1, FLT3
14chronic myeloproliferative disease10.1FLT3, JAK2
15essential thrombocythemia10.1KIT, JAK2
16leukemia, acute promyelocytic10.1RUNX1, FLT3
17leukemia, acute myeloid10.1KIT, RUNX1, FLT3
18acute myeloid leukemia, adult10.1RUNX1, FLT3, KIT
19thyroid cancer10.1HRAS, FLT3
20thrombocytosis10.0FLT3, JAK2
21kidney cancer10.0KIT, HRAS, FLT3
22leukemia, juvenile myelomonocytic10.0RUNX1, HRAS, FLT3
23eosinophilia10.0JAK2, CBFB
24cleidocranial dysplasia9.9RUNX1, RUNX2, CBFB
25polycythemia vera9.9FLT3, JAK2, KIT
26hypersensitivity reaction type ii disease9.9HRAS, FLT3, RUNX1
27chromosomal triplication9.9JAK2, FLT3, RUNX1
28retinoblastoma9.8RUNX1, RUNX2, HRAS
29down syndrome9.8FLT3, RUNX1, JAK2
30prostate cancer9.8JAK2, FLT3, HRAS
31gastric cancer, somatic9.8CBFB, RUNX1, RUNX2
32glioblastoma9.8JAK2, KIT, HRAS
33refractory anemia9.7KIT, JAK2, FLT3, RUNX1
34chronic myelomonocytic leukemia9.7JAK2, RUNX1, FLT3, KIT
35melanoma9.7HRAS, KIT, JAK2, FLT3
36sarcoma9.7RUNX1, JAK2, KIT, HRAS
37ovarian cancer, somatic9.6HRAS, RUNX1, JAK2
38precursor t-cell acute lymphoblastic leukemia9.6RUNX1, FLT3, JAK2, HRAS
39rheumatoid arthritis9.6RUNX1, RUNX2, JAK2
40myelodysplastic syndrome9.5KIT, CBFB, JAK2, RUNX1, FLT3
41colorectal cancer9.5JAK2, RUNX1, HRAS
42bone marrow cancer9.5JAK2, RUNX1, HRAS, KIT, FLT3
43hematologic cancer9.5JAK2, KIT, HRAS, FLT3, RUNX1
44burkitt lymphoma9.4FLT3, RUNX2, RUNX1, HRAS, JAK2
45leukemia, chronic myeloid9.3HRAS, KIT, RUNX1, CBFB, JAK2, FLT3
46acute leukemia9.3CBFB, KIT, JAK2, HRAS, RUNX1, FLT3
47leukemia, acute lymphoblastic9.3CBFB, HRAS, KIT, RUNX1, FLT3, JAK2
48breast cancer9.0RUNX2, RUNX1, JAK2, CBFB, KIT, HRAS

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to core binding factor acute myeloid leukemia

Symptoms for Core Binding Factor Acute Myeloid Leukemia

About this section

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

About this section

Drug clinical trials:

Search ClinicalTrials for Core Binding Factor Acute Myeloid Leukemia

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

About this section

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

About this section

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

31
Myeloid, Bone marrow, Bone, Eye

Animal Models for Core Binding Factor Acute Myeloid Leukemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

35 (show all 18)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.6RUNX2, CBFB, KIT, HRAS
2MP:00053708.6KIT, CBFB, RUNX2, RUNX1
3MP:00028738.2HRAS, KIT, JAK2, RUNX1
4MP:00030128.2RUNX1, RUNX2, CBFB, KIT, HRAS
5MP:00053888.2RUNX1, RUNX2, CBFB, KIT, HRAS
6MP:00053858.1RUNX1, RUNX2, CBFB, KIT, HRAS
7MP:00053798.0RUNX2, JAK2, KIT, HRAS
8MP:00053808.0RUNX1, JAK2, CBFB, KIT
9MP:00036318.0RUNX1, RUNX2, CBFB, KIT, HRAS
10MP:00020067.7HRAS, KIT, CBFB, JAK2, FLT3, RUNX1
11MP:00053977.5RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
12MP:00053877.5RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
13MP:00053907.5RUNX1, RUNX2, JAK2, CBFB, KIT, HRAS
14MP:00107717.4RUNX1, RUNX2, JAK2, CBFB, KIT, HRAS
15MP:00053847.4RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
16MP:00053787.1RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
17MP:00053767.0RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
18MP:00107687.0RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT

Publications for Core Binding Factor Acute Myeloid Leukemia

About this section

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show all 45)
idTitleAuthorsYear
1
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. (25753065)
2015
2
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission. A French Acute Myeloid leukemia Intergroup trial. (25715404)
2015
3
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. (25348871)
2014
4
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. (24793731)
2014
5
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. (25088818)
2014
6
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. (25449688)
2014
7
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. (25006122)
2014
8
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). (24844781)
2014
9
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. (24972769)
2014
10
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. (23783394)
2013
11
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. (23053179)
2013
12
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. (23321257)
2013
13
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. (23677335)
2013
14
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? (24319183)
2013
15
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. (23266036)
2013
16
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. (23716553)
2013
17
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. (23646898)
2013
18
Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. (24226631)
2013
19
Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. (22145956)
2012
20
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. (22234698)
2012
21
Impact of residual normal metaphases in core binding factor acute myeloid leukemia. (21928314)
2012
22
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. (22886749)
2012
23
Treatment strategies in patients with core-binding factor acute myeloid leukemia. (21755276)
2011
24
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. (21715005)
2011
25
Core binding factor acute myeloid leukemia (CBF-AML) in MAcxico: a single institution experience. (21574542)
2011
26
Core-binding factor acute myeloid leukemia. (22032582)
2011
27
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. (20709669)
2010
28
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? (19468270)
2009
29
Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. (19644024)
2009
30
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. (19126873)
2009
31
Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. (19603346)
2009
32
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. (18981008)
2008
33
Core binding factor acute myeloid leukemia. (18692691)
2008
34
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. (18297529)
2008
35
Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. (18940681)
2008
36
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. (18841055)
2008
37
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. (17485551)
2007
38
Core binding factor acute myeloid leukemia. (16728942)
2006
39
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). (16598313)
2006
40
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. (16015387)
2005
41
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. (16110030)
2005
42
Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia. (15068897)
2004
43
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. (15289486)
2004
44
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. (15124687)
2004
45
Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. (14695213)
2003

Variations for Core Binding Factor Acute Myeloid Leukemia

About this section

Expression for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section
Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 38)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.7KIT, FLT3
2
Show member pathways
Development Flt3 signaling58
9.5FLT3, HRAS
3
Show member pathways
9.4RUNX1, HRAS
49.4RUNX2, CBFB
59.3HRAS, RUNX2
69.3RUNX2, RUNX1
7
Show member pathways
9.2FLT3, KIT, HRAS
8
Show member pathways
9.2FLT3, KIT, HRAS
9
Show member pathways
9.2HRAS, KIT, FLT3
10
Show member pathways
9.2FLT3, KIT, HRAS
11
Show member pathways
9.1HRAS, JAK2
129.1JAK2, HRAS
139.1JAK2, HRAS
149.1JAK2, HRAS
159.1HRAS, JAK2
16
Show member pathways
Immune response IL 3 activation and signaling pathway58
9.1HRAS, JAK2
17
Show member pathways
EPO Receptor Signaling36
EPO signaling pathway36
9.1HRAS, JAK2
18
Show member pathways
9.1HRAS, JAK2
19
Show member pathways
MAPK Cascade36
Immune response Oncostatin M signaling via MAPK in human cells58
Oncostatin M Signaling Pathway36
9.1JAK2, HRAS
209.1HRAS, JAK2
219.0JAK2, RUNX2
228.9FLT3, RUNX2, RUNX1
238.9KIT, JAK2, FLT3
24
Show member pathways
8.8JAK2, KIT, HRAS
25
Show member pathways
8.8HRAS, KIT, JAK2
26
Show member pathways
Signaling events mediated by Stem cell factor receptor (c-Kit)36
8.8HRAS, KIT, JAK2
27
Show member pathways
Development EDNRB signaling58
Development ACM2 and ACM4 activation of ERK58
Cell adhesion Integrin inside out signaling58
Development G Proteins mediated regulation MARK ERK signaling58
Signal transduction IP3 signaling58
Development Angiotensin signaling via PYK258
Development EPO induced MAPK pathway58
8.8JAK2, KIT, HRAS
28
Show member pathways
8.8HRAS, KIT, JAK2
298.8JAK2, KIT, HRAS
30
Show member pathways
8.7FLT3, JAK2, HRAS
31
Show member pathways
Signal transduction PTEN pathway58
8.6HRAS, KIT, FLT3, RUNX1
328.6HRAS, KIT, FLT3, RUNX1
338.5RUNX2, JAK2, HRAS
34
Show member pathways
8.3FLT3, JAK2, KIT, HRAS
35
Show member pathways
8.3FLT3, JAK2, KIT, HRAS
36
Show member pathways
8.3FLT3, JAK2, KIT, HRAS
37
Show member pathways
8.3HRAS, KIT, JAK2, FLT3
38
Show member pathways
8.3FLT3, JAK2, KIT, HRAS

Compounds for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Compounds related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 43)
idCompoundScoreTop Affiliating Genes
1tandutinib4310.1KIT, FLT3
2pkc 4124310.0KIT, FLT3
3ag-12964310.0KIT, FLT3
4su54164310.0KIT, FLT3
5ponatinib49 1211.0KIT, FLT3
6sunitinib43 49 1212.0KIT, FLT3
717-(allylamino)-17-demethoxygeldanamycin439.8KIT, FLT3
8methylcellulose439.8KIT, FLT3
9sorafenib43 49 1211.7FLT3, KIT
10beta-tyrosine439.7JAK2, KIT
11lestaurtinib43 5910.6JAK2, FLT3
12hydroxyurea43 49 1211.3KIT, JAK2
13valine439.1JAK2, KIT, HRAS
14herbimycin a43 5910.1HRAS, JAK2, FLT3
15arsenite43 2410.1JAK2, FLT3, RUNX1
16phenylalanine439.1JAK2, KIT, HRAS
17doxorubicin43 49 1211.0RUNX1, FLT3, KIT, HRAS
1812-o-tetradecanoylphorbol 13-acetate438.9HRAS, JAK2, RUNX1
19gp 130438.8FLT3, JAK2, KIT, HRAS
20imatinib43 49 1210.8RUNX1, FLT3, JAK2, KIT
21phosphotyrosine438.8HRAS, KIT, JAK2, FLT3
22butyrate438.7RUNX1, RUNX2, JAK2
23rapamycin438.7HRAS, KIT, JAK2, FLT3
24phosphoinositide438.7FLT3, JAK2, KIT, HRAS
25aspartate438.7FLT3, JAK2, KIT, HRAS
26ly294002438.7RUNX2, JAK2, HRAS
27leucine438.7HRAS, KIT, JAK2
28pge2438.6HRAS, JAK2, RUNX2
29atp43 289.6FLT3, JAK2, KIT, HRAS
30pd 98,059438.5HRAS, KIT, JAK2, RUNX2
31steroid438.5RUNX2, JAK2, KIT, HRAS
32nitric oxide43 24 1210.4RUNX2, JAK2, KIT, HRAS
33estrogen438.4RUNX2, JAK2, KIT, HRAS
34cycloheximide438.4KIT, JAK2, RUNX2
35glucose438.3HRAS, KIT, JAK2, RUNX2
36threonine438.2RUNX1, FLT3, JAK2, KIT, HRAS
37thymidine43 249.2HRAS, KIT, JAK2, FLT3, RUNX2
38phosphatidylinositol438.1RUNX2, FLT3, JAK2, KIT, HRAS
39serine438.0RUNX1, RUNX2, JAK2, KIT, HRAS
40oligonucleotide437.6HRAS, KIT, JAK2, FLT3, RUNX2, RUNX1
41vegf437.6RUNX1, RUNX2, FLT3, JAK2, KIT, HRAS
42retinoic acid43 248.6RUNX1, RUNX2, FLT3, JAK2, KIT, HRAS
43tyrosine437.6RUNX1, RUNX2, FLT3, JAK2, KIT, HRAS

GO Terms for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 25)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of phosphatidylinositol 3-kinase activityGO:00435529.9KIT, FLT3
2embryonic hemopoiesisGO:00351629.8KIT, RUNX1
3definitive hemopoiesisGO:00602169.8CBFB, RUNX1
4myeloid cell differentiationGO:00300999.8CBFB, RUNX1
5stem cell differentiationGO:00488639.8RUNX2, KIT
6T cell differentiationGO:00302179.7KIT, RUNX2
7visual learningGO:00085429.7HRAS, KIT
8positive regulation of tyrosine phosphorylation of Stat5 proteinGO:00425239.6KIT, JAK2
9positive regulation of MAP kinase activityGO:00434069.5FLT3, HRAS
10cell maturationGO:00484699.5CBFB, RUNX2
11myeloid progenitor cell differentiationGO:00023189.5KIT, FLT3, RUNX1
12hemopoiesisGO:00300979.5KIT, FLT3, RUNX1
13positive regulation of MAPK cascadeGO:00434109.5FLT3, KIT, HRAS
14positive regulation of tyrosine phosphorylation of Stat3 proteinGO:00425179.5KIT, JAK2
15erythrocyte differentiationGO:00302189.5JAK2, KIT
16positive regulation of sequence-specific DNA binding transcription factor activityGO:00510919.3KIT, JAK2
17positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.2KIT, JAK2, FLT3
18peptidyl-tyrosine phosphorylationGO:00181089.2KIT, JAK2, FLT3
19protein autophosphorylationGO:00467779.2FLT3, JAK2, KIT
20cytokine-mediated signaling pathwayGO:00192219.1FLT3, JAK2, KIT
21osteoblast differentiationGO:00016499.1CBFB, RUNX2
22positive regulation of cell migrationGO:00303359.1HRAS, KIT, JAK2
23activation of MAPKK activityGO:00001869.0HRAS, JAK2
24negative regulation of cell proliferationGO:00082858.8HRAS, JAK2, FLT3
25positive regulation of cell proliferationGO:00082848.1RUNX2, FLT3, JAK2, KIT, HRAS

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1transmembrane receptor protein tyrosine kinase activityGO:00047149.6FLT3, KIT
2repressing transcription factor bindingGO:00704919.3RUNX2, RUNX1
3phosphatidylinositol 3-kinase bindingGO:00435489.3JAK2, FLT3
4protein homodimerization activityGO:00428039.2KIT, FLT3, RUNX1
5protein tyrosine kinase activityGO:00047139.0KIT, JAK2
6ATP bindingGO:00055247.9KIT, JAK2, FLT3, RUNX2, RUNX1
7protein bindingGO:00055156.9RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT

Products for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Core Binding Factor Acute Myeloid Leukemia

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet